[{"id":"bec56339-c58d-4adf-b9c5-7c33103ad8b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694871","created_at":"2023-01-23T14:59:43.962Z","updated_at":"2024-07-02T16:35:01.360Z","phase":"Phase 2","brief_title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05694871","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • RB1 • CDK4","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-23"},{"id":"c84d8944-d78f-409a-b988-e7289ade4c23","acronym":"FIRST-NEC","url":"https://clinicaltrials.gov/study/NCT06393816","created_at":"2024-05-04T04:28:40.403Z","updated_at":"2024-07-02T16:35:05.677Z","phase":"Phase 2","brief_title":"FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum","source_id_and_acronym":"NCT06393816 - FIRST-NEC","lead_sponsor":"Centre Leon Berard","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-06"},{"id":"447deee0-48df-4d5d-a0f4-8e3810a39c90","acronym":"DepiSCARRH","url":"https://clinicaltrials.gov/study/NCT03026998","created_at":"2021-01-18T14:53:55.583Z","updated_at":"2024-07-02T16:35:06.766Z","phase":"","brief_title":"MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)","source_id_and_acronym":"NCT03026998 - DepiSCARRH","lead_sponsor":"Institut Curie","biomarkers":" RB1","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/19/2017","start_date":" 03/19/2017","primary_txt":" Primary completion: 03/01/2034","primary_completion_date":" 03/01/2034","study_txt":" Completion: 03/01/2034","study_completion_date":" 03/01/2034","last_update_posted":"2024-04-30"},{"id":"ee1f7ecf-9bc4-4111-8b8a-fd3789290137","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926181","created_at":"2021-06-15T17:53:11.788Z","updated_at":"2024-07-02T16:35:07.351Z","phase":"Phase 2","brief_title":"Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04926181","lead_sponsor":"Rahul Aggarwal","biomarkers":" RB1 • SYP","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-04-26"},{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"2a4bf351-5891-4378-a18a-58000cb4e271","acronym":"","url":"https://clinicaltrials.gov/study/NCT00342797","created_at":"2021-01-18T01:11:06.648Z","updated_at":"2024-07-02T16:35:15.944Z","phase":"","brief_title":"Retinoblastoma Biomarker Study","source_id_and_acronym":"NCT00342797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 2136","initiation":"Initiation: 11/17/1993","start_date":" 11/17/1993","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 03/06/2024","study_completion_date":" 03/06/2024","last_update_posted":"2024-03-07"},{"id":"7b687780-b61c-439e-9b4e-196b803f25c3","acronym":"PAveMenT","url":"https://clinicaltrials.gov/study/NCT04360941","created_at":"2023-12-22T20:17:07.096Z","updated_at":"2024-07-02T16:35:25.341Z","phase":"Phase 1","brief_title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","source_id_and_acronym":"NCT04360941 - PAveMenT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • PIK3CA • TMB • PTEN • RB1","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation","tags":["PD-L1 • PIK3CA • TMB • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation • PD-L1 negative • RB1 mutation • PTEN expression • PIK3CA expression • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-22"},{"id":"71483d11-4da8-4e39-ba54-3c80e749d899","acronym":"NIRBTEST","url":"https://clinicaltrials.gov/study/NCT04164134","created_at":"2021-01-18T20:19:15.421Z","updated_at":"2024-07-02T16:35:42.030Z","phase":"","brief_title":"New Strategies to Detect Cancers in Carriers of Mutations in RB1","source_id_and_acronym":"NCT04164134 - NIRBTEST","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 378","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-07-25"},{"id":"fb76e3be-1fa8-41fb-ba96-a942800db45c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02193724","created_at":"2021-01-18T10:14:45.089Z","updated_at":"2024-07-02T16:36:39.707Z","phase":"","brief_title":"Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma","source_id_and_acronym":"NCT02193724","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" RB1 • MYCN","pipe":" | ","alterations":" MYCN amplification • RB1 mutation","tags":["RB1 • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/04/2014","start_date":" 11/04/2014","primary_txt":" Primary completion: 08/23/2019","primary_completion_date":" 08/23/2019","study_txt":" Completion: 08/23/2019","study_completion_date":" 08/23/2019","last_update_posted":"2020-10-23"},{"id":"e3d70ec4-f879-4157-9ebe-eaa36fa0b809","acronym":"","url":"https://clinicaltrials.gov/study/NCT00690469","created_at":"2021-01-18T02:34:51.214Z","updated_at":"2024-07-02T16:36:54.774Z","phase":"","brief_title":"Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers","source_id_and_acronym":"NCT00690469","lead_sponsor":"Children's Oncology Group","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 234","initiation":"Initiation: 06/02/2008","start_date":" 06/02/2008","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2019-10-08"}]